Open access
Open access
Powered by Google Translator Translator

ASCO 2018: Pembrolizumab vs. Chemotherapy as First-line Therapy for Advanced Non-Small Cell Lung Cancer

7 Jun, 2018 | 02:20h | UTC

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study (link to abstract)

Commentaries: 2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More – The ASCO Post (free) AND ‘End of an Era’ for Chemo in Non-Small Cell Lung Cancer – Medscape (free registration required)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.